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A B S T R A C T
Background
Mastitis can be caused by ineffective positioning of the baby at the breast or restricted feeding. Infective mastitis is commonly caused
by Staphylococcus aureus. The prevalence of mastitis in breastfeeding women may reach 33%. Effective milk removal, pain medication
and antibiotic therapy have been the mainstays of treatment.
Objectives
This review aims to examine the effectiveness of antibiotic therapies in relieving symptoms for breastfeeding women with mastitis with
or without laboratory investigation.
Search methods
We searched the Cochrane Pregnancy and Childbirth Group’s Trials Register (30 September 2012), contacted investigators and other
content experts known to us for unpublished trials and scanned the reference lists of retrieved articles.
Selection criteria
We selected randomised controlled trials (RCTs) and quasi-RCTs comparing the effectiveness of various types of antibiotic therapies
or antibiotic therapy versus alternative therapies for the treatment of mastitis.
Data collection and analysis
Two review authors independently assessed trial quality and extracted data. When in dispute, we consulted a third author.
Main results
Two trials met the inclusion criteria. One small trial (n = 25) compared amoxicillin with cephradine and found no significant difference
between the two antibiotics in terms of symptom relief and abscess formation. Another, older study compared breast emptying alone as
’supportive therapy’ versus antibiotic therapy plus supportive therapy, and no therapy. The findings of the latter study suggested faster
clearance of symptoms for women using antibiotics, although the study design was problematic.
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Authors’ conclusions
There is insufficient evidence to confirm or refute the effectiveness of antibiotic therapy for the treatment of lactational mastitis. There
is an urgent need to conduct high-quality, double-blinded RCTs to determine whether antibiotics should be used in this common
postpartum condition.
P L A I N L A N G U A G E S U M M A R Y
Antibiotics for mastitis in breastfeeding women
Inflammation of the breast, or mastitis, can be infective or non-infective. Infective mastitis is one of the most common infections
experienced by breastfeeding women. The condition (infective or not) varies in severity, ranging from mild symptoms with some local
inflammation, redness, warmth and tenderness in the affected breast through to more serious symptoms including fever, abscess and
septicaemia, which may require hospitalisation. Recovery can take time, and there may be substantial discomfort for the affectedmother
and her baby. Mastitis usually occurs during the first three months after birth and results in the mother being confined to bed for one
day, followed by restricted activity. The condition is associated with decreased milk secretion, decreased productivity, and in difficulties
caring for the baby. This burden to mothers, along with the cost of care, the potential negative impact on continuation of breastfeeding,
and the danger of serious complications such as septicaemia, makes mastitis a serious condition which warrants early diagnosis and
effective therapy. The review included two studies and approximately 125 women. One study compared two different antibiotics, and
there were no differences between the two antibiotics for symptom relief. A second study comparing no treatment, breast emptying,
and antibiotic therapy, with breast emptying suggested more rapid symptom relief with antibiotics. There is very little evidence on the
effectiveness of antibiotic therapy, and more research is needed.
B A C K G R O U N D
Description of the condition
Mastitis is an inflammatory condition of the breast, usually asso-
ciated with lactation (WHO 2000). Hence, it is also known as
lactational mastitis (Hughes 1989) or puerperal mastitis (Editorial
1976). An estimated 2% to 33% of breastfeeding women develop
lactational mastitis (Buescher 2001; Fetherston 1998; Foxman
2002; Jonsson 1994; Kaufmann 1991; Kinlay 1998; Marshall
1975; Riordan 1990; Vogel 1999). Population-based studies in
Australia reported that 15% to 20% of women during the first six
months after delivery were affected, while a cohort study of Amer-
ican women reported that 10% of women experienced mastitis
during the three months following the birth. Mastitis may recur:
a New Zealand study of 350 lactating mothers showed a 8.5%
recurrence rate.
The primary cause of mastitis is milk stasis (Hughes 1989), which
may ormaynot be associatedwith infection.Mastitis can be caused
by ineffective positioning of the baby at the breast, limited feeding
(in cases where the mother is introducing formula feeding), or re-
stricted feeding, all of which may result in milk stasis and mastitis.
In infective mastitis, Staphylococcus aureus and Staphylococcus albus
are the commonest organisms found on laboratory investigation
(Novy 1984; Riordan 1990). Escherichia coli (Lawrence 1999) and
streptococci are found less frequently (Novy 1984). Delayed, inap-
propriate or inadequate treatment may result in unnecessary dis-
continuation of breastfeeding, breast tissue damage, recurrence,
and substantial cost (Evans 1995).
Clinical symptoms of mastitis include unilateral breast pain, red-
ness (erythema) and swelling, and may be associated with flu-like
symptoms (fever, chills and aches). Unilateral erythema, oedema
and tenderness of the affected breast are usually present on exam-
ination. In contrast, engorgement of the breast is normally bilat-
eral and uncomfortable rather than acutely painful; and in cases of
breast abscess, a fluctuating, tender and hard breast mass is found
with overlying erythema (Bedinghaus 1997; Hager 1992; Ogle
1988). Milk leucocyte count, bacteria colony count and culture
may be useful investigations to differentiate infective from non-
infective mastitis (Thomsen 1984).
Description of the intervention
The principles of treating mastitis include supportive counselling
and supportive therapy (bed rest, increased fluids), effective milk
removal (by encouraging the continuation of breastfeeding and
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assessing how the baby is feeding; helping the mother to adjust
positioning and attachment if necessary; and milk expression),
symptomatic treatment (pain medication, use of anti-inflamma-
tory agents), antibiotic therapy (Walker 1999), probiotic therapy
(Jimenez 2008) and other agents such as nisin (Fernandez 2008).
Although efficient milk removal is the mainstay of treatment, an-
tibiotics are usually prescribed to cover possible bacterial infec-
tions. These include penicillin, dicloxacillin and cephalosporins
(Hager 1992; Marchant 2002) for staphylococcal and streptococ-
cal infections; for gram-negative organisms, cephalexin or amoxi-
cillin may be appropriate (Olsen 1990).
The use of antibiotics in the treatment of mastitis varies world-
wide, and researchers have been unable to reach a consensus on
whether to prescribe antibiotics for women with lactational mas-
titis. Osterman 2000 underscored the benefit of prescribing both
antibiotic therapy and supportive treatment in the presence of in-
fective agents. They prescribed antibiotics after bacterial cultiva-
tion for 61% of participants in a cohort of lactational women with
mastitis. The authors argued that since breastmilk potentially con-
tained pathogenic bacteria, the majority of the mothers should be
treated with antibiotics. However, Kvist 2004 only treated 9% of
breast inflammation with antibiotics. A study inWestern Australia
treated 85% of participants with inflammatory breast symptoms
with antibiotics (Kvist 2005).
Matheson 1988 concluded that phenoxymethylpenicillin failed to
stop abscess formation in 20% of mothers suffering from mastitis
and that the majority of them recovered without antibiotics. Amir
2004a stated that low incidence of abscess formation (0.1% in
their study) raised the question as to whether antibiotic therapy is
appropriate for allmotherswith symptomsof breast inflammation.
They reported that only 2.9% (95%confidence interval 1.0 to 6.7)
of women who took antibiotics for mastitis developed abscesses.
There has also been argument about the type of antibiotic chosen
for breastfeeding women suffering from mastitis. Practice relating
to the choice of antibiotic therapy has varied widely. An audit of
the management of mastitis in the emergency department of Mel-
bourne Hospital, Australia, showed that the majority of women
withmastitis received flucloxacillin (91women out of 111), a beta-
lactamase stable penicillin closely related to cloxacillin, as recom-
mended by Australian Antibiotic Guideline (1996) (Amir 2004b).
Amir reported that, due to adverse hepatic events, dicloxacillin
should replace flucloxacillin (Amir 2004b). A prospective study (n
= 840) conducted in the US between 1994 and1998 reported that
86% of women with mastitis received antibiotics, most of whom
were on cephalexin (46%). The rest received amoxicillin (7%),
ampicillin (7%) and amdinocillin clavulanate (7%). No cultures
were performed because of cost restrictions (Foxman 2002). An-
other recent publication (Eglash 2006) reported a chart review of
64 women with lactational mastitis presenting to a lactation spe-
cialist between 1997 and 2002; these women received routine an-
tibiotic therapy at the time inclusive of cephalexin, dicloxacillin,
erythromycin, amoxicillin and clindamycin. The choice of antibi-
otics was based on the mother’s and her baby’s records of allergies
and intolerances; mother’s preference regarding the frequency of
antibiotic administration; bacterial culture and sensitivities, and
medication cost.
Why it is important to do this review
There is little consensus on who should be prescribed antibiotics,
the most appropriate antibiotic to use, the best time to begin
treatment and how long the treatment should continue. Most
studies have focused on the effectiveness of emptying the breast
and the timing of treatment, rather than on the type of antibiotics
used (Crepinsek 2010; Devereux 1970; Kinlay 1998; Thomsen
1984). Use of laboratory investigation before antibiotic therapy is
not consistent, and type of antibiotic chosen depends on physician
choice rather than scientific proof. There is also little information
on the cost-effectiveness of different therapies.
O B J E C T I V E S
The objective of this review is to examine the effectiveness of an-
tibiotic therapies in relieving symptoms for breastfeeding women
who have mastitis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) or quasi-RCTs.
Types of participants
Lactating women who were diagnosed with mastitis, with or with-
out laboratory investigations. We have excluded breast engorge-
ment and breast abscess from this review.
Types of interventions
Intervention
Antibiotic therapy (various routes of administration, dosages, du-
rations or timing of administration).
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Control
Placebo, no treatment, other supportive treatments such as breast
emptying or another antibiotic of a different class.
Types of outcome measures
Primary outcomes
1. Symptom improvement reported by women
2. Symptom improvement by clinical assessment
3. Continued breastfeeding
4. Resolution of infection as confirmed by laboratory test
Secondary outcomes
1. Adverse drug reactions following antibiotic therapy
2. Neonatal complications (e.g. neonatal colitis)
3. Hospitalisation
4. Costs
Search methods for identification of studies
Electronic searches
We searched the Cochrane Pregnancy and Childbirth Group’s
Trials Register by contacting the Trials Search Co-ordinator (30
September 2012).
The Cochrane Pregnancy and Childbirth Group’s Trials Register
is maintained by the Trials Search Co-ordinator and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE;
3. weekly searches of EMBASE;
4. handsearches of 30 journals and the proceedings of major
conferences;
5. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Details of the search strategies for CENTRAL, MEDLINE and
EMBASE, the list of handsearched journals and conference pro-
ceedings, and the list of journals reviewed via the current aware-
ness service can be found in the ‘Specialized Register’ section
within the editorial information about the Cochrane Pregnancy
and Childbirth Group.
Trials identified through the searching activities described above
are each assigned to a review topic (or topics). The Trials Search
Co-ordinator searches the register for each review using the topic
list rather than keywords.
For details of additional searching carried out in the initial version
of the review, see: Appendix 1.
Searching other resources
We contacted investigators (named in the retrieved articles) and
other content experts known to us for unpublished trials. In addi-
tion, we looked for relevant trials in the references of the retrieved
articles.
We did not apply any language restrictions.
Data collection and analysis
For methods used in the previous version of this review, see
Appendix 3.
For this update, two review authors independently assessed for
inclusion the two reports that were identified as a result of the
updated search. We did not include either. If we identify new
trials for inclusion in future updates of this review, we will use the
methods described in Appendix 4.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of studies awaiting classification.
Two studiesmet the pre-stated inclusion criteria in this review.One
study had two treatment arms (amoxicillin versus cephradine) for
the treatment of mastitis (Hager 1996). Another study compared
antibiotic therapy versus no therapy and/or non-pharmacological
therapy (breast emptying) and the unit of analysis was the breast
rather than the woman (Thomsen 1984).
Results of the search
In the initial version of the review, we identified 11 references
(10 through the database search, and one through handsearching)
(Amir 2004b). We reviewed titles and inspected abstracts. We ex-
cluded seven studies at initial screening for one or more of the
following reasons: not related to mastitis, not a RCT, intervention
of interest was not used or no relevant outcome was reported. We
considered four studies potentially eligible for inclusion, but, after
inspection of the full paper, excluded two of them. We have pro-
vided the reasons for exclusion in the Characteristics of excluded
studies table.
Following an updated search inMarch 2010, we excluded a further
two reports (Fernandez 2008; Jimenez 2008).
Following an updated search in September 2012, we excluded one
report (Arroyo 2010) and one is awaiting translation fromChinese
(Zhou 2009), see Characteristics of studies awaiting classification.
4Antibiotics for mastitis in breastfeeding women (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Included studies
Participants
Hager 1996 included 13 participants in the amoxicillin group and
12 in the cephradine group. Thomsen 1984 included 55 ’cases’
(individual breasts) in each of three arms (antibiotic plus breast
emptying, breast emptying alone and no treatment). We have as-
sumed that the number of women included in the analysis was
approximately 100, although the actual number of women suf-
fering from infective mastitis is not provided in the paper. (The
paper described findings for women with both infective and non-
infective mastitis (n = 213). The total number of affected breasts
was 339, so overall, approximately 60% of the women had both
breasts affected. The number of infected breasts was 165 (55 in
each of three treatment groups); assuming that the same propor-
tions of women with infective versus non-infective mastitis had
both breasts affected, this would mean that approximately 100
women had infective mastitis and are included in the analysis in
this review.)
Participants included in these trials were lactating mothers with
symptoms of mastitis such as persistent tenderness of breast,
swelling, redness, decreasedmilk secretion, fever or breast discom-
fort. Leucocyte count was also used in Thomsen 1984 as an in-
clusion criterion for treatment.
Intervention
Hager 1996 did not include any placebo or non-treatment control
group. The treatment regimens compared in this trial were oral
amoxicillin, 500 mg every eight hours for seven days versus oral
cephradine, 500 mg every eight hours for seven days. Participants
in both groups were advised to continue breastfeeding and to ap-
ply warm, moist compresses every four to six hours (Hager 1996).
Thomsen 1984 included two control groups, one where women
received no treatment and a second where there was breast emp-
tying. The treatment group in this study received the following
antibiotics: penicillin 500,000 IU three per day for six days, oral
ampicillin 500 mg, four per day for six days and erythromycin
500 mg twice per day for six days (Thomsen 1984).
Outcomes
In both included studies, resolution of symptoms (fever, erythema
and tenderness) was the main outcome measure. Thomsen 1984
reported on continuation of normal lactation in a follow-up visit
two weeks after treatment. Both studies measured several negative
outcomes, including persistence of symptoms, impaired milk se-
cretion and recurrence of infection. Duration of follow-up was 30
days for Hager 1996 and 14 days for Thomsen 1984.
Excluded studies
Weexcluded seven studies at initial screening for one ormore of the
following reasons: not related to mastitis, not a RCT, intervention
of interest was not used or no relevant outcome was reported. We
considered four studies potentially eligible for inclusion, but, after
inspection of the full paper, excluded two of them.
Following updated searches in March 2010, and September 2012,
we excluded a further three reports (Arroyo2010; Fernandez 2008;
Jimenez 2008). One study report is awaiting classification (Zhou
2009) as it needs to be translated.
We have provided the reasons for exclusion in the Characteristics
of excluded studies table.
Risk of bias in included studies
See Characteristics of included studies table.
Allocation
Both included studies were RCTs. However, only one of the stud-
ies adequately described the method of allocation concealment.
Generation of randomisation sequence was not reported in either
study, but one study reported concealment of allocation using pre-
sealed opaque envelopes (Hager 1996).
Blinding
Investigatorswere blinded inHager 1996 and themethodof blind-
ing was considered adequate The other study did not describe the
method of blinding (Thomsen 1984).
Incomplete outcome data
The assessment of pre-determined variables in each study was
based primarily on follow-up. There was no reported loss to fol-
low-up in either of these studies.
Selective reporting
All expected outcomes were reported in one study (Hager 1996).
In the other study, it was unclear whether or not outcomes had
been selectively reported (Thomsen 1984).
Other potential sources of bias
Baseline characteristics were balanced in one study (Hager 1996),
and in the other study it was not possible to tell whether other
sources of bias were present (Thomsen 1984).
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Effects of interventions
As the studies identified were not sufficiently similar and not of
sufficient quality, we did not do a meta-analysis and have there-
fore presented data, and discussed results, separately for the two
included studies. In future updates of the review, as new studies
emerge, it may be possible to add further comparisons and, where
appropriate, combine findings in a meta-analysis.
Primary outcomes
Proportion of participants with resolution of symptoms or
improvement
Symptom improvement reported by women (outcome number 1)
was not measured in either of the included studies. Both studies
included findings relating to the second primary outcome (symp-
tom improvement assessed by clinicians). However, comparison
between the two studies was impossible since one was comparing
antibiotic therapy with breast emptying versus breast emptying or
no treatment, while the other was comparing two different types
of antibiotic therapy.
One study assessed symptom improvement assessed by clinicians
after seven days, but did not provide information on the continu-
ation of breastfeeding (Hager 1996). In this study all women pre-
scribed cephradine and most of those prescribed amoxicillin had
symptom improvement after seven days; there were no statistically
significant differences between groups (risk ratio (RR) 0.85, 95%
confidence interval (CI) 0.65 to 1.12) (Analysis 1.1).
Thomsen 1984 assessed continuation of breastfeeding after 14
days. In this study, analysis was carried out on cases (breasts) rather
than a participant basis. Each case was a breast with mastitis symp-
toms. Cases were divided into three groups depending on labo-
ratory investigations; cases with milk stasis only (n = 126), cases
with non-infective inflammation (n = 48), and cases with infective
mastitis (n = 165). Only cases in the third group (those with infec-
tive disease) were considered relevant to this review. This infective
mastitis group was divided into three subgroups: cases receiving
no treatment (n = 55), breast emptying only with no antibiotic
therapy (n = 55), or receiving antibiotic therapy plus emptying
the breast (n = 55). We carried out two separate comparisons: first
women receiving no treatment versus women receiving antibiotics
with breast emptying; and second, breast emptying alone versus
antibiotics with breast emptying.
For cases with infective mastitis, the outcome was good in 15%
of cases if there was no treatment and in most cases (96%) for
women undergoing antibiotic therapy with breast emptying (RR
6.63, 95% CI 3.48 to 12.60) (Analysis 2.1). (The outcome was
considered either as good if inflammatory symptoms disappeared
followed by normal lactation two weeks after the initial diagno-
sis; or bad when symptoms persisted for more than 14 days. Im-
paired milk secretion, recurrence of infection, or progression of
the symptoms to sepsis or breast abscesses were also considered
as bad outcomes.) When antibiotic therapy with breast emptying
was compared with breast emptying alone, again those receiving
antibiotic therapy were more likely to have a good outcome (RR
1.89, 95% CI 1.45 to 2.47) (Analysis 3.1).
Women were also likely to recover more quickly if they received
antibiotics with a mean duration of symptoms of 6.7 days in the
no-treatment group, 4.2 days in the breast emptying group and
2.1 days in the antibiotic therapy with breast emptying group.
Sensitivity analysis
In the Thomsen 1984 study, the unit of analyses was breasts rather
than individual women, so for women who contributed two in-
fected breasts to the analysis, the response to treatment in each
breast was unlikely to have been independent. We therefore con-
ducted a series of sensitivity analyses where we made several dif-
ferent assumptions. For example, we assumed that 28 women (in
both groups) each had two infected breasts; this effectively reduced
the sample size to half the original size. The results of the sensitivity
analyses (based on differing assumptions) made little difference to
the results, although the smaller sample sizes (when women rather
than single breasts were the unit of analysis) resulted in wider con-
fidence intervals.
Secondary outcomes
Thomsen 1984 did not report whether or not there were any ad-
verse events or drug reactions following antibiotic therapy. Hager
1996, however, mentioned that there were no adverse side effects
to the antibiotics administered. The women were asked about
compliance with dosing at the return visit, and all indicated that
they had taken their medication as prescribed with no complica-
tions. Neonatal complications, hospitalisation and costs were not
reported in either study.
Relapse rate
Recurrence within 30 days was reported for one woman (7.6%)
in the amoxicillin arm and two women (16.6%) in the cephradine
arm (Hager 1996). Thomsen 1984 had an overall recurrence of
12 cases in the infective mastitis arm. The recurrence rate for the
antibiotic therapy group was not stated.
D I S C U S S I O N
Themain finding of the review is that there is insufficient evidence
available to confidently evaluate the effect of antibiotic therapy
on mastitis. Controlled scientific studies such as randomised con-
trolled trials (RCTs) are lacking in this field. Observational studies
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suggest that the type of antibiotic prescribed depends on physi-
cian preference, without any scientific proof. Various classes of
antibiotics are prescribed without laboratory investigation. These
include penicillins and cephalosporins (Amir 2004b; Marchant
2002; Olsen 1990). Antibiotic resistance may arise as a result of
tendency to prescribe broad-spectrum antibiotics. It is possible
that lower-cost, narrower-spectrum antibiotics based on bacterial
culture might be as effective as the use of higher cost, broad-spec-
trum antibiotics. The findings of this review were not able to shed
light on these questions.
Antibiotic therapy can be directed by leucocyte count and the sus-
ceptibility tests of isolated bacteria (Hager 1996). This approach
was used by Thomsen 1984, who examined the effect of antibiotic
therapy versus supportive therapy. They categorised 213 women
with mastitis into three groups: milk stasis (with bacteria < 103/
mL; leucocytes < 106/mL), non-infective inflammation (bacteria
< 103/mL; leucocytes > 106/mL), and infective mastitis (bacteria
> 103/mL; leucocytes > 106/mL). For those in the latter group, an-
tibiotic therapy was based on sensitivity cultivation. Women who
received antibiotic therapy achieved the fastest symptom clearance
of 2.1 days, as opposed to the other two groups (6.7 days if under
no treatment and 4.2 days if under supportive therapy). More-
over, 11% of cases with no intervention developed an abscess,
while none in the group treated with antibiotic therapy suffered
from any abscess, indicating a better outcome if antibiotics were
used in cases with mastitis. However, there were limitations in
the Thomsen 1984 study. Although it was a RCT, the study was
conducted 25 years ago and it lacked several features of a well-
designed trial: the process of concealment was not mentioned and
there was no placebo used.
Current practice for treating mastitis varies widely. There is a lack
of properly-designed RCTs to evaluate the best antibiotic therapy
for treating mastitis. Hager 1996 is the only RCT suitable for re-
view that compared two types of antibiotics (amoxicillin, cephra-
dine) in a small group of 25 women with mastitis. The author-
calculated sample size for each arm of this study was 72; however,
the number of included women was 13 for the amoxicillin group
and 12 in the cephradine group. Therefore, this study was un-
derpowered and was unable to detect differences in the predeter-
mined treatment outcome. The authors were unable to run a Chi²
test as the number of women in cross-tabulated cells was less than
five. Therefore, the Fisher Exact test was used and there was no
significant difference between the two arms in terms of treatment
failure.
Hager 1996 suggested that both oral antibiotics appeared equally
effective in the treatment of sporadic acute puerperal mastitis.
Moreover, there is a lack of information on the possible side effects
of antibiotics on neonates when they are used for treatment of
mastitis.
Our updated literature search was unfruitful in finding any studies
that looked at some of the pre-determined outcomes of this re-
view, such as hospitalisation and costs. We found two new studies
(Fernandez 2008; Jimenez 2008) focusing on other methods of
treatment using probiotics and other agents such as nisin. These
studies introduced lactobacillus strains and bacteriocin nisin as
the potential and effective alternative therapy for mastitis. How-
ever, since the focus of our study is antibiotic therapy we did not
include them in our review. It is recommended that a new title
would specifically look into the effectiveness of these alternative
therapies. The need for comprehensive RCTs on mastitis and an-
tibiotic therapy still remains.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is little evidence from the RCTs currently available to evalu-
ate the effect of antibiotic therapy on mastitis. The included trials
failed to meet some of the criteria for methodological quality, and
the outcome measures used were too varied for comparisons to be
made between studies.
Implications for research
There is an urgent need for high-quality, large randomised
placebo-controlled trials. Future research should be designed so
as to have adequate power (sample size), adequate allocation con-
cealment, blinding of outcome assessors, and clear description of
follow-up, to allow appropriate comparisons between various an-
tibiotic therapies or placebo groups, or both. Primary outcomes of
this review, including symptom improvement reported by women
or found by clinical assessment, the effect of continued breastfeed-
ing versus no breastfeeding and the result of treating the infective
mastitis based on laboratory investigation, should be further in-
vestigated. Secondary outcomes such as neonatal complications,
hospitalisation, cost of treatment and adverse reactions following
antibiotic therapy, should also be considered. Each and every one
of these variables are important in terms of maternal and child
health.We recommend a comprehensive RCT to investigate all of
the above mentioned variables.
1. Symptom improvement reported by women.
2. Symptom improvement by clinical assessment.
3. Continued breastfeeding.
4. Resolution of infection as confirmed by laboratory test.
A C K N OW L E D G E M E N T S
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We are grateful to Professor Jackie Ho who provided us with her
constructive comments.
As part of the pre-publication editorial process, this review has
been commented on by three peers (an editor and two referees
who are external to the editorial team), a member of the Pregnancy
and Childbirth Group’s international panel of consumers and the
Group’s Statistical Adviser.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Hager 1996
Methods Randomised: method of randomisation is not mentioned.
Adequate concealment of allocation is mentioned inclusive of using pre-sealed, opaque
envelopes.
Double blind: no. It was mentioned that investigators were blinded.
Intention-to-treat not mentioned.
Follow-up is described. Patients were seen for follow-up visits in 7 days.
25 recruited and no drop-outs.
Design: parallel.
Participants 25 lactating mothers with Sporadic Acute Puerperal Mastitis (SAPM) were recruited for
this study.
Inclusion criteria: 3 criteria of oral temperature of 37.56ºC, tenderness on palpation of
the breast and segmental erythema was needed to include a participant.
Exclusion criteria: maternal age of < 18 years, documented allergy to penicillins or
cephalosporins, and antibiotic therapy within the previous 30 days.
Baseline characteristics such as age, parity, history of mastitis, or history of diabetes
mellitus was similar between the 2 groups
Interventions The treatment regimens were oral amoxicillin, 500 mg every 8 h for 7 days, or oral
cephradine, 500 mg every 8 h for 7 days. Continuation of breastfeeding and usage of
warm and moist compresses to the involved breast every 4-6 h was recommended for all
patients
All patients presented to outpatient clinic and visited by single physician. Patients were
instructed to notify the physician if their temperature remained > 37.56ºC (> 99.6ºF)
after 48 hrs or if they were unable to comply with the antibiotic regimen
Outcomes Outcomeswere inclusive of resolution of mastitis, namely fever, erythema and tenderness
Notes University of Kentucky Medical Center Outpatient Clinic patients enrolled from July
1991 until December 1993.
Informed consent signed by all patients. Historical information and study data were
recorded on pre-coded data sheet
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method is not mentioned.
Allocation concealment (selection bias) Low risk Adequate concealment of allocation is
mentioned inclusive of using pre-sealed,
opaque envelopes
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Hager 1996 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk It was mentioned that investigators were
blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Follow-up is described. Patients were seen
for follow-up visits in 7 days.
25 recruited and no drop-outs.
Selective reporting (reporting bias) Low risk All expected outcomes appear to have been
reported.
Other bias Low risk Groups appear balanced for baseline char-
acteristics (apart from duration of symp-
toms - see Table 1, page 99)
Thomsen 1984
Methods Randomised: method of randomisation is not mentioned.
Allocation concealment: there is no mention of patient allocation. Antibiotic therapy
was rather directed by susceptibility tests of the isolated bacteria. Unit of allocations was
“mothers” but the unit analysed in the results was shown as “breasts”.
Double blind: no. It is unclear whether patient or outcome assessor was blinded.
Intention-to-treat not mentioned.
Follow-up is not described clearly. From definition of bad outcome it can be implied
that patients have been visited 2 weeks after the attack.
No drop-outs.
Design: parallel.
Participants 213 nursing women with the diagnosis of infective mastitis (presence and persistence of
tenderness, swelling, redness, heat, and decreased milk secretion) were recruited for this
study. Diagnosis was made based on clinical symptoms, leucocyte count and anaerobic/
aerobic bacteria cultivation. The unit of analysis in this study was not women but rather
single breasts (339 breasts). There were 3 groups. Group 1 included those with milk
stasis (< 106 leucocytes and < 103 bacteria) (number of breasts = 126) and group 2 were
inclusive of non-infective mastitis (> 106 leucocytes and < 103 bacteria) (number of =
48). Group 3 consisted of 165 inflammatory breasts with proven infective mastitis (>
106 leucocytes and > 103 bacteria)
This final group (included in this review) was then randomly assigned to 3 subgroups
with 55 cases in each group:
Those with no therapy (subgroup 1), standard of care therapy (subgroup 2) and finally
cases of antibiotic therapy (subgroup 3)
Inclusion criteria: the presence and persistence of tenderness, swelling, redness, heat, and
decreased milk secretion.
Exclusion criteria were not mentioned.
Baseline characteristics were not mentioned.
All patients presented to Kommune hospital, Aarhus in Denmark. There is no mention
if patients were visited in outpatient clinic
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Thomsen 1984 (Continued)
Interventions The treatment regimens contained penicillin 500,000 IU 3 per day for 6 days, oral
ampicillin 500 mg, 4 per day for 6 days or erythromycin 500 mg 2 times per day
for 6 days. In control group non-intervention therapy was adopted which consisted of
emptying the breast every 6 h by nursing the baby followed by expression by hand or
mechanical suction
Outcomes Outcomewas considered as good if symptoms ofmastitis disappeared followed by normal
lactation throughout 2 weeks after the attack
Notes Study was done in 1983 (no exact date is mentioned) in Department of Obstetrics and
Gynecology, Kommunehospital, Aarhus in Denmark.
There is no mention if patient signed any consent form. Study had been approved by
local ethical committee
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method is not mentioned.
Allocation concealment (selection bias) Unclear risk Antibiotic therapy was rather directed by
susceptibility tests of the isolated bacteria
Blinding (performance bias and detection
bias)
All outcomes
High risk It is unclear whether women or outcome
assessors were blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Follow-up is not described clearly. From the
definition of bad outcome it can be implied
that patients were visited 2 weeks after the
attack. There is no report of drop-outs or
for any of the subgroups
Selective reporting (reporting bias) Unclear risk Unclear from study report. No study pro-
tocol.
Other bias Unclear risk No baseline characteristics table.
h: hours
IU: international units
SAPM: sporadic acute puerperal mastitis
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Amir 2004b Allocation is not clear.
Randomisation: yes.
Participants: 10 randomised breastfeeding women with cracked nipples colonised with Staphylococcus aureus were
recruited out of 135 women who were originally found to be eligible.
In the placebo arm, 2 out of 5 women continued to take the capsules.
Intervention: 7-day course of either an oral antibiotic (flucloxacillin) or identical placebo capsules.
Researcher did not complete the study due to logistic problems. This study is therefore an unfinished RCT
Arroyo 2010 One study arm used antibiotic but the two control groups used different forms of oral lactobacilli and did not use
placebo, no treatment, or other supportive treatments such as breast emptying or another antibiotic of a different
class
Fernandez 2008 Bacteriocin nisin was used for treatment group and no report of antibiotic usage was studied
Gerstner 1987 Information in this briefly presented study is more concentrated on postpartum infections in general rather than
mastitis
Jimenez 2008 Lactobacillus strains isolated from breast milk were used as a mode of treatment and there was no report of
antibiotic therapy
RCT: randomised controlled trial
Characteristics of studies awaiting assessment [ordered by study ID]
Zhou 2009
Methods Randomised controlled trial.
Parallel.
Participants 198 women with acute mastitis for Yueyang Hospital of Integrated Traditional Chinese andWesternMedicine, China
99 cases in each group.
Interventions Treatment group: oral cefradine.
Control group: kneading and dispersing manipulation.
Outcomes Local breast lump size; clinical symptoms; adverse reactions
Notes Information available from English abstract, full report in Chinese and currently being translated
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D A T A A N D A N A L Y S E S
Comparison 1. Amoxicillin versus cephradine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Symptom improvement assessed
by clinician
1 25 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.65, 1.12]
Comparison 2. Antibiotic therapy with breast emptying versus no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Symptom improvement assessed
by clinician and continuous
breastfeeding
1 110 Risk Ratio (M-H, Fixed, 95% CI) 6.63 [3.48, 12.60]
Comparison 3. Antibiotic therapy with breast emptying versus breast emptying alone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Symptom improvement assessed
by clinician and continuous
breastfeeding
1 110 Risk Ratio (M-H, Fixed, 95% CI) 1.89 [1.45, 2.47]
Comparison 4. Sensitivity analyses: antibiotic therapy versus no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Assuming that in both groups
both breasts are infected:
symptom improvement
assessed by a clinician
1 56 Risk Ratio (M-H, Fixed, 95% CI) 6.75 [2.72, 16.77]
2 Assuming that in both groups
60% of women have 2 breasts
infected and 40% 1 infected
1 68 Risk Ratio (M-H, Fixed, 95% CI) 6.4 [2.84, 14.44]
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Comparison 5. Sensitivity analyses: antibiotic therapy versus breast emptying
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Assuming that in both groups
both breasts are infected:
symptom improvement
assessed by a clinician
1 56 Risk Ratio (M-H, Fixed, 95% CI) 1.93 [1.32, 2.81]
2 Assuming that in both groups
60% of women have 2 breasts
infected and 40% 1 infected
1 68 Risk Ratio (M-H, Fixed, 95% CI) 1.88 [1.33, 2.66]
Analysis 1.1. Comparison 1 Amoxicillin versus cephradine, Outcome 1 Symptom improvement assessed by
clinician.
Review: Antibiotics for mastitis in breastfeeding women
Comparison: 1 Amoxicillin versus cephradine
Outcome: 1 Symptom improvement assessed by clinician
Study or subgroup Amoxicillin Cephradine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hager 1996 11/13 12/12 100.0 % 0.85 [ 0.65, 1.12 ]
Total (95% CI) 13 12 100.0 % 0.85 [ 0.65, 1.12 ]
Total events: 11 (Amoxicillin), 12 (Cephradine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.15 (P = 0.25)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours cephradine Favours amoxycillin
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Analysis 2.1. Comparison 2 Antibiotic therapy with breast emptying versus no treatment, Outcome 1
Symptom improvement assessed by clinician and continuous breastfeeding.
Review: Antibiotics for mastitis in breastfeeding women
Comparison: 2 Antibiotic therapy with breast emptying versus no treatment
Outcome: 1 Symptom improvement assessed by clinician and continuous breastfeeding
Study or subgroup Antibiotic therapy No treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Thomsen 1984 53/55 8/55 100.0 % 6.63 [ 3.48, 12.60 ]
Total (95% CI) 55 55 100.0 % 6.63 [ 3.48, 12.60 ]
Total events: 53 (Antibiotic therapy), 8 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 5.77 (P < 0.00001)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours no treatment Favours antibiotics
Analysis 3.1. Comparison 3 Antibiotic therapy with breast emptying versus breast emptying alone,
Outcome 1 Symptom improvement assessed by clinician and continuous breastfeeding.
Review: Antibiotics for mastitis in breastfeeding women
Comparison: 3 Antibiotic therapy with breast emptying versus breast emptying alone
Outcome: 1 Symptom improvement assessed by clinician and continuous breastfeeding
Study or subgroup Antibiotics Breast emptying Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Thomsen 1984 53/55 28/55 100.0 % 1.89 [ 1.45, 2.47 ]
Total (95% CI) 55 55 100.0 % 1.89 [ 1.45, 2.47 ]
Total events: 53 (Antibiotics), 28 (Breast emptying)
Heterogeneity: not applicable
Test for overall effect: Z = 4.73 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours breast emptying Favours antibiotics
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Analysis 4.1. Comparison 4 Sensitivity analyses: antibiotic therapy versus no treatment, Outcome 1
Assuming that in both groups both breasts are infected: symptom improvement assessed by a clinician.
Review: Antibiotics for mastitis in breastfeeding women
Comparison: 4 Sensitivity analyses: antibiotic therapy versus no treatment
Outcome: 1 Assuming that in both groups both breasts are infected: symptom improvement assessed by a clinician
Study or subgroup Antibiotic therapy No treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Thomsen 1984 27/28 4/28 100.0 % 6.75 [ 2.72, 16.77 ]
Total (95% CI) 28 28 100.0 % 6.75 [ 2.72, 16.77 ]
Total events: 27 (Antibiotic therapy), 4 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 4.11 (P = 0.000039)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours no treatment Favours antibiotics
Analysis 4.2. Comparison 4 Sensitivity analyses: antibiotic therapy versus no treatment, Outcome 2
Assuming that in both groups 60% of women have 2 breasts infected and 40% 1 infected.
Review: Antibiotics for mastitis in breastfeeding women
Comparison: 4 Sensitivity analyses: antibiotic therapy versus no treatment
Outcome: 2 Assuming that in both groups 60% of women have 2 breasts infected and 40% 1 infected
Study or subgroup Antibiotic therapy No treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Thomsen 1984 32/34 5/34 100.0 % 6.40 [ 2.84, 14.44 ]
Total (95% CI) 34 34 100.0 % 6.40 [ 2.84, 14.44 ]
Total events: 32 (Antibiotic therapy), 5 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 4.47 (P < 0.00001)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours no treatment Favours antibiotics
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Analysis 5.1. Comparison 5 Sensitivity analyses: antibiotic therapy versus breast emptying, Outcome 1
Assuming that in both groups both breasts are infected: symptom improvement assessed by a clinician.
Review: Antibiotics for mastitis in breastfeeding women
Comparison: 5 Sensitivity analyses: antibiotic therapy versus breast emptying
Outcome: 1 Assuming that in both groups both breasts are infected: symptom improvement assessed by a clinician
Study or subgroup Antibiotics Breast emptying Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Thomsen 1984 27/28 14/28 100.0 % 1.93 [ 1.32, 2.81 ]
Total (95% CI) 28 28 100.0 % 1.93 [ 1.32, 2.81 ]
Total events: 27 (Antibiotics), 14 (Breast emptying)
Heterogeneity: not applicable
Test for overall effect: Z = 3.41 (P = 0.00064)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours breast emptying Favours antibiotics
Analysis 5.2. Comparison 5 Sensitivity analyses: antibiotic therapy versus breast emptying, Outcome 2
Assuming that in both groups 60% of women have 2 breasts infected and 40% 1 infected.
Review: Antibiotics for mastitis in breastfeeding women
Comparison: 5 Sensitivity analyses: antibiotic therapy versus breast emptying
Outcome: 2 Assuming that in both groups 60% of women have 2 breasts infected and 40% 1 infected
Study or subgroup Antibiotics Breast emptying Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Thomsen 1984 32/34 17/34 100.0 % 1.88 [ 1.33, 2.66 ]
Total (95% CI) 34 34 100.0 % 1.88 [ 1.33, 2.66 ]
Total events: 32 (Antibiotics), 17 (Breast emptying)
Heterogeneity: not applicable
Test for overall effect: Z = 3.58 (P = 0.00035)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours breast emtying Favours antibiotics
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A P P E N D I C E S
Appendix 1. Search strategy
This strategy was run in CENTRAL (The Cochrane Library 2007, Issue 4), MEDLINE (January 1966 to 2007) and EMBASE (January
1985 to 2007)
#1 MASTITIS (subject heading)
#2 mastitis
#3 puerper*
#4 breastfeeding
#5 (breast next feeding)
#6 breast-feeding
#7 lactation*
#8 nursing
#9 antibio*
#10 treatment*
#11 ANTI-BACTERIAL AGENTS (MeSH) (Note: we used Antibiotic agent in EMBASE)
#12 therap*
#13 (#1 or #2)
#14 (#3 or #4 or #5 or #6 or #7 or #8)
#15 (#9 or #10 or #11 or #12)
#16 (#13 and #14 and #15)
Appendix 2. 2 Search strategy (June 20th 2012)
1 exp Mastitis/ or mastitis.mp. or exp Granulomatous Mastitis/ (10755)
2 breastfeeding.mp. or exp Breast Feeding/ (27103)
3 exp Breast Feeding/ or breast next feeding.mp. or exp Lactation/ (52662)
4 breast-feeding.mp. or exp Breast Feeding/ (27418)
5 exp Lactation Disorders/ or Lactation/ or lactation.mp. (42383)
6 nursing.mp. (426127)
7 exp Anti-Bacterial Agents/ or antibio.mp. (487245)
8 treatment.mp. or exp Therapeutics/ (5009754)
9 therap.mp. (25)
10 2 or 3 or 4 or 5 or 6 (491228)
11 7 or 8 or 9 (5304972)
12 1 and 10 and 11 (983)
13 exp Random Allocation/ or exp Research Design/ or randomized control trial.mp. or exp Clinical Trials as Topic/ (503055)
14 12 and 13 (67)
15 limit 14 to (humans and yr=“2010 -Current”) (2)
Appendix 3. Data collection and analysis for previous versions
Selection of studies
Two review authors independently assessed the titles and abstracts of identified studies. Where we could not make a clear decision on
the basis of the title or abstract, we considered the study to be relevant. We retrieved the full text of relevant studies. If the retrieved
articles were not written in English, we obtained a translation. Two review authors independently examined the retrieved articles to
assess whether they satisfied the inclusion criteria. We resolved disagreement by consensus with a third review author.
Two review authors independently double entered data. A third review author checked to ensure concordance.
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Assessment of methodological quality of included studies
We assessed the quality of included studies using the criteria in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2008). We assessed each study for quality in terms of sequence generation, allocation sequence concealment, blinding, incomplete
outcome data, selective outcome reporting and ‘other’ potential sources of bias. We reported methods used for the generation of the
randomisation sequence for each trial.
(1) Sequence generation
We considered the sequence generation to be adequate if the following or similar methods were used: repeated coin tossing, throwing
dice or dealing previously shuffled cards or computer generation of random numbers. We considered any other non-random type of
sequence generation inadequate.
(2) Allocation concealment
We assigned a quality score for concealment to each trial, using the following criteria:
• adequate concealment of allocation, such as telephone randomisation, consecutively numbered sealed opaque envelopes;
• unclear whether adequate concealment of allocation;
• inadequate concealment of allocation, such as random number tables, sealed envelopes.
Where the method of allocation was unclear, we had planned to contact study authors to provide further details.
(3) Blinding (blinding of participants, researchers and outcome assessment)
We assessed blinding using the following criteria:
• blinding of participants (yes/no/unclear);
• blinding of caregiver (yes/no/unclear);
• blinding of outcome assessment (yes/no/unclear).
(4) Incomplete outcome data (loss of participants, e.g. withdrawals, drop-outs, protocol deviations)
We assessed completeness to follow-up using the following criteria:
• less than 5% of participants excluded;
• 5% to 10% of participants excluded;
• more than 10% and up to and including 20% of participants excluded.
We planned to exclude studies from analysis, because of the risk of bias, if:
(A) more than 20% of participants were lost to follow-up;
(B) more than 20% of participants were not analysed according to randomisation groups and where it was not possible to restore
participants to the correct group;
(C) where there was a large difference (more than 10%) in withdrawal of participants between groups.
We also considered selective outcome reporting and other potential sources of bias such as time lag, location bias and language bias.
Data extraction and management
We designed a form to extract data. Two review authors extracted the data independently onto standardised, structured tables. We
resolved differences in opinion as above. We performed data entry using the Review Manager software (RevMan 2008). If data were
unclear, we tried to contact authors of the original reports to provide further details.
Data analysis
We used the Cochrane Review Manager software (RevMan 2008) to analyse the data.
21Antibiotics for mastitis in breastfeeding women (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Dichotomous data
For dichotomous data, we have reported results as risk ratios with 95% confidence intervals.
Continuous data
For continuous data, we planned to calculate the mean difference if outcomes were measured in the same way between trials. We
planned to use the standardised mean difference with 95% confidence interval to combine trials measuring the same outcome, but
using different methods. We recorded evidence of skewness.
Measures of treatment effect
We used a fixed-effect model for combining data in the absence of significant heterogeneity if trials were sufficiently similar. In the case
of heterogeneity, we planned to use a random-effects model.
Assessment of heterogeneity
We would have applied tests of heterogeneity between trials, if appropriate, using the I² test. If we identified high levels of heterogeneity
among the trials (I² exceeding 50%), we would have explored it by prespecified subgroup analysis and by performing sensitivity analysis.
We would have used a random-effects meta-analysis as an overall summary if this had been considered appropriate.
Sensitivity analyses
We would have carried out sensitivity analysis to explore the effect of trial quality. We would have excluded studies of poor quality
(with poor allocation concealment or levels of attrition above 20%) in the analysis in order to assess for any substantive difference to
the overall results.
The analysed units in Thomsen 1984 study were breasts, rather than women (213 women or 339 breasts). The sample would have
included women with either both or only one breast affected, and where both breasts were infected the treatment effect in each breast
would not be independent. Therefore, we carried out an exploratory sensitivity analysis to look at various different scenarios, for
example, where we assumed that all women had two affected breasts, or where half had only one breast affected.
Subgroup analyses
We had planned subgroup analyses classifying whole trials by interaction tests as described by Deeks 2001. We planned to carry out
the following subgroup analyses:
1. dosage of antibiotics used (e.g. antibiotic A dosage 250 mg versus antibiotic A dosage 400 mg);
2. drug reaction: (maternal drug reaction, infant/child drug reaction).
Appendix 4. Data collection and analysis for future updates
Selection of studies
Two review authors will independently assess for inclusion all the potential studies we identify as a result of the search strategy. We will
resolve any disagreement through discussion or, if required, we will consult the third review author.
We will design a form to extract data. For eligible studies, two review authors will extract the data using the agreed form.We will resolve
discrepancies through discussion or, if required, we will consult the third review author. Data will be entered into Review Manager
software (RevMan 2011) and checked for accuracy.
When information regarding any of the above is unclear, we will attempt to contact authors of the original reports to provide further
details.
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Assessment of risk of bias in included studies
Two review authors will independently assess risk of bias for each study using the criteria outlined in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). Any disagreement will be resolved by discussion or by involving a third assessor.
(1) Random sequence generation (checking for possible selection bias)
We will describe for each included study the method used to generate the allocation sequence in sufficient detail to allow an assessment
of whether it should produce comparable groups.
We will assess the method as:
• low risk of bias (any truly random process, e.g. random number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even date of birth; hospital or clinic record number);
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection bias)
We will describe for each included study the method used to conceal allocation to interventions prior to assignment and will assess
whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment.
We will assess the methods as:
• low risk of bias (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-opaque envelopes, alternation; date of birth);
• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for possible performance bias)
We will describe for each included study the methods used, if any, to blind study participants and personnel from knowledge of which
intervention a participant received. We will consider that studies are at low risk of bias if they were blinded, or if we judge that the lack
of blinding would be unlikely to affect results. We will assess blinding separately for different outcomes or classes of outcomes.
We will assess the methods as:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible detection bias)
We will describe for each included study the methods used, if any, to blind outcome assessors from knowledge of which intervention a
participant received. We will assess blinding separately for different outcomes or classes of outcomes.
We will assess methods used to blind outcome assessment as:
• low, high or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition bias due to the amount, nature and handling of incomplete
outcome data)
We will describe for each included study, and for each outcome or class of outcomes, the completeness of data including attrition and
exclusions from the analysis. We will state whether attrition and exclusions were reported and the numbers included in the analysis at
each stage (compared with the total randomised participants), reasons for attrition or exclusion where reported, and whether missing
data were balanced across groups or were related to outcomes. Where sufficient information is reported, or can be supplied by the trial
authors, we will re-include missing data in the analyses which we undertake.
We will assess methods as:
• low risk of bias (e.g. no missing outcome data; missing outcome data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data imbalanced across groups; ‘as treated’ analysis done with substantial
departure of intervention received from that assigned at randomisation);
• unclear risk of bias.
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(5) Selective reporting (checking for reporting bias)
We will describe for each included study how we investigated the possibility of selective outcome reporting bias and what we found.
We will assess the methods as:
• low risk of bias (where it is clear that all of the study’s pre-specified outcomes and all expected outcomes of interest to the review
have been reported);
• high risk of bias (where not all the study’s pre-specified outcomes have been reported; one or more reported primary outcomes
were not pre-specified; outcomes of interest are reported incompletely and so cannot be used; study fails to include results of a key
outcome that would have been expected to have been reported);
• unclear risk of bias.
(6) Other bias (checking for bias due to problems not covered by (1) to (5) above)
We will describe for each included study any important concerns we have about other possible sources of bias.
(7) Overall risk of bias
Wewill make explicit judgements about whether studies are at high risk of bias, according to the criteria given in theHandbook (Higgins
2011). With reference to (1) to (6) above, we will assess the likely magnitude and direction of the bias and whether we consider it is
likely to impact on the findings. We will explore the impact of the level of bias through undertaking sensitivity analyses - see Sensitivity
analysis.
Measures of treatment effect
Dichotomous data
For dichotomous data, we will present results as summary risk ratio with 95% confidence intervals.
Continuous data
For continuous data, we will use the mean difference if outcomes are measured in the same way between trials. We will use the
standardised mean difference to combine trials that measure the same outcome, but use different methods.
Unit of analysis issues
Cluster-randomised trials
Wewill include cluster-randomised trials in the analyses along with individually-randomised trials. Their sample sizes or standard errors
will be adjusted using themethods described in theHandbook using an estimate of the intracluster correlation co-efficient (ICC) derived
from the trial (if possible), or from another source. If ICCs from other sources are used, this will be reported and sensitivity analyses
conducted to investigate the effect of variation in the ICC. If we identify both cluster-randomised trials and individually-randomised
trials, we plan to synthesise the relevant information. We will consider it reasonable to combine the results from both if there is little
heterogeneity between the study designs and the interaction between the effect of intervention and the choice of randomisation unit
is considered to be unlikely.
We will also acknowledge heterogeneity in the randomisation unit and perform a separate meta-analysis.
Cross-over trials
Cross-over trials will be excluded from this review.
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Dealing with missing data
For included studies, levels of attrition will be noted. The impact of including studies with high levels of missing data in the overall
assessment of treatment effect will be explored by using sensitivity analysis.
For all outcomes, analyses will be carried out, as far as possible, on an intention-to-treat basis i.e. we will attempt to include all
participants randomised to each group in the analyses. The denominator for each outcome in each trial will be the number randomised
minus any participants whose outcomes are known to be missing.
Assessment of heterogeneity
We will assess statistical heterogeneity in each meta-analysis using the T², I² and Chi² statistics. We will regard heterogeneity as
substantial if I² is greater than 50% and either T² is greater than zero, or there is a low P value (less than 0.10) in the Chi² test for
heterogeneity. If we identify substantial heterogeneity (above 50%), we will explore it by pre-specified subgroup analysis.
Assessment of reporting biases
If there are 10 or more studies in the meta-analysis we will investigate reporting biases (such as publication bias) using funnel plots. We
will assess funnel plot asymmetry visually, and use formal tests for funnel plot asymmetry. For continuous outcomes we will use the
test proposed by Egger 1997, and for dichotomous outcomes we will use the test proposed by Harbord 2006. If asymmetry is detected
in any of these tests or is suggested by a visual assessment, we will perform exploratory analyses to investigate it.
Data synthesis
We will carry out statistical analysis using the Review Manager software (RevMan 2011). We will use fixed-effect meta-analysis for
combining data where it is reasonable to assume that studies are estimating the same underlying treatment effect: i.e. where trials are
examining the same intervention, and the trials’ populations and methods are judged sufficiently similar. If there is clinical heterogeneity
sufficient to expect that the underlying treatment effects differ between trials, or if substantial statistical heterogeneity is detected, we
will use random-effects meta-analysis to produce an overall summary if an average treatment effect across trials is considered clinically
meaningful. The random-effects summary will be treated as the average range of possible treatment effects and we will discuss the
clinical implications of treatment effects differing between trials. If the average treatment effect is not clinically meaningful, we will
not combine trials. If we use random-effects analyses, the results will be presented as the average treatment effect with 95% confidence
intervals, and the estimates of T² and I².
Subgroup analysis and investigation of heterogeneity
If we identify substantial heterogeneity, we will investigate it using subgroup analyses and sensitivity analyses. We will consider whether
an overall summary is meaningful, and if it is, use random-effects analysis to produce it.
We plan to carry out the following subgroup analyses:
1. dosage of antibiotics used (e.g. antibiotic A dosage 250 mg versus antibiotic A dosage 400 mg);
2. drug reaction: (maternal drug reaction, infant/child drug reaction).
Subgroup analyses will be restricted to the review’s primary outcomes.
We will assess differences between subgroups by interaction tests available within RevMan (RevMan 2011).
Sensitivity analysis
We plan to carry out sensitivity analyses to explore the effect of trial quality assessed by concealment of allocation, high attrition rates,
or both, with poor quality studies being excluded from the analyses in order to assess whether this makes any difference to the overall
result.
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WH A T ’ S N E W
Last assessed as up-to-date: 23 November 2012.
Date Event Description
23 November 2012 New citation required but conclusions have not
changed
Two trials identified from an updated search in
September 2012 - one excluded (Arroyo 2010) and
one awaiting translation (Zhou 2009).
30 September 2012 New search has been performed Search updated in September 2012.
H I S T O R Y
Protocol first published: Issue 3, 2005
Review first published: Issue 1, 2009
Date Event Description
19 March 2010 New search has been performed Search updated. Two new studies identified but excluded (Fernandez 2008;
Jimenez 2008).
4 February 2009 Amended Corrected typographical error.
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